A Short-Course Dose Escalation Strategy Could Improve Ability to Reach Target Dose of Adjuvant Abemaciclib in High-Risk Early-Stage HR-positive, HER2-negative Breast Cancer By Ogkologos - November 21, 2025 386 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the TRADE study Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR Woman Celebrates Beating Cancer By Creating Christmas Tree Mannequins With A... December 6, 2019 Finding Hope in the New Year During COVID-19 and Cancer January 6, 2021 Aiming to Prevent Cancer Cases, ESMO Calls Against Misleading Alcohol-Labelling Following... December 3, 2025 Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated... October 12, 2026 Load more HOT NEWS With Longer Follow-Up, Trastuzumab Deruxtecan Continues to Demonstrate Superior Efficacy Over... Building on Success, Maximizing Opportunities: NCI’s Annual Plan & Budget Proposal EMA Recommends Extension of Therapeutic Indications for Lisocabtagene Maraleucel Cancer Survivor And His Organ Donor Run NYC Marathon Together To...
